The Medicine Won't Do Your Ethics For You

The political version of this problem, how psychedelic experience gets assimilated to any ideology, is the subject of a companion piece on why psychedelic experiences aren't inherently progressive.

A supervisee once described a client she wanted to refer for psilocybin work. The client had a first-degree family history of psychosis and a current pattern that worried me. I asked how she was thinking about the screening. She said, with real warmth, "I know, but the medicine will take him where he needs to go." She is a good clinician. And in that one sentence, the guard was already down.

Psychedelic exceptionalism is the belief that psychedelics are a special category of intervention, inherently healing, categorically safe in the right hands, and morally good in a way ordinary medicine is not. It shows up as the sense that these substances do not need the same scrutiny we would apply to any other potent drug, because their nature is benevolent. It is the therapeutic version of a much older idea: that some things are too sacred to question.

I understand the pull. I have spent decades in this field precisely because I think the medicines have real clinical value. But "real clinical value" and "inherently healing" are different claims, and the gap between them is where patients get hurt.

Exceptionalism does its damage quietly, at the exact junctions where a clinician is supposed to be most careful.

Screening. When you believe the medicine is fundamentally safe and good, contraindications start to feel like obstacles to a deserved experience rather than protections. A psychosis history, a cardiac risk, an unstable situation: each becomes something to work around instead of a reason to pause. The documented adverse effects of psychedelics are not rare enough to wave off, and they cluster in exactly the populations that enthusiasm is most tempted to admit.

Informed consent. Consent depends on an honest account of risk and uncertainty. Exceptionalism erodes that account. If you are quietly certain the outcome will be good, you will undersell what could go wrong, and a client who trusts you will absorb your certainty as their own.

Power. The altered state heightens suggestibility and widens the clinician-client differential. I have written before about the power dynamics that psychedelic states intensify. Exceptionalism makes that worse, because a clinician who believes the medicine is doing the real work is less likely to examine what they themselves are doing with that heightened influence.

Outcome claims. Belief in inherent healing invites overclaiming. It turns "shows promise for carefully selected patients" into "this changes people," and that inflation is not harmless. It sets patient expectations that the evidence cannot support, and it is the same inflation the $10,000 training economy runs on. Hype is good for enrollment. It is not good for consent.

It is worth noticing that the cautious position is also the mainstream one. When the American Psychological Association engaged Congress on psychedelic-assisted therapy, its leaders emphasized the need for quality, unbiased research and care models that include real psychotherapy, rather than taking an advocacy stance for the treatments themselves. The professional posture is that psychologists lead here as experts in assessment, ethics, and research, not as boosters. Exceptionalism, for all its warmth, is out of step with that. Skepticism is not disloyalty to the field. It is the field's actual standard.

The alternative to exceptionalism is not the mirror-image cynicism that dismisses the medicines entirely. Liberation psychology gives us a better frame: take the suffering seriously, take the structures that produce it seriously, and refuse the easy story that any single intervention is liberation on its own. Hope and skepticism are not in tension. The clinician who most wants these treatments to help is the one who should most want them screened, consented, and claimed accurately, because that is what keeps them available and credible.

Before your next psychedelic-adjacent case, ask yourself four questions:

1. Am I treating a contraindication as an obstacle to overcome rather than a signal to heed?
2. Have I described what could go wrong as concretely as what could go right?
3. Am I accounting for how much weight my own confidence carries in an altered state?
4. Would my outcome language survive being read aloud to a skeptical peer-review panel?

If any answer makes you wince, that is the exceptionalism talking, and it is worth listening to the wince.

Psychedelic exceptionalism is the belief that psychedelics are inherently healing and morally good, and therefore need less scrutiny than other potent interventions. Clinically, it is a risk because it softens screening, consent, and outcome claims. Naming it is the first step to practicing with the same rigor you would bring to any potent treatment.

No. The cautious posture is the mainstream one. Major professional bodies emphasize unbiased research, real psychotherapy, and ethical rigor rather than advocacy for the treatments themselves. The clinician who wants these medicines to help is the one who should most want them screened, consented, and described accurately, because that is what keeps them credible and available.

Hold hope and skepticism at once. Take the client's suffering seriously while refusing the story that any one intervention is inherently curative. Describe risk as concretely as benefit, use moderation language ("shows promise for carefully selected patients"), and check whether your confidence is doing work in the room that the evidence has not earned.

Exceptionalism is easiest to catch when you have a concrete ethical framework to hold your practice against. This course builds that frame for real clinical decisions, not abstractions.

Peter H. Addy, PhD, LPC, LMHC is a Portland-based licensed therapist and the founder of Psychedelic Affirming Education, an NBCC-approved continuing education provider for licensed mental health professionals and Oregon Psilocybin Services facilitators. His research background includes work at Yale School of Medicine on psychedelic substances.